Hypera S.A. (HYPMY)

OTCMKTS · Delayed Price · Currency is USD
3.970
+0.120 (3.12%)
Oct 14, 2025, 3:45 PM EDT
3.12%
Market Cap2.46B
Revenue (ttm)1.22B
Net Income (ttm)136.30M
Shares Outn/a
EPS (ttm)0.21
PE Ratio18.03
Forward PE8.44
Dividend0.14 (3.57%)
Ex-Dividend DateOct 6, 2025
Volume5
Average Volume10,514
Open3.775
Previous Close3.850
Day's Range3.710 - 3.970
52-Week Range2.640 - 5.120
Beta0.30
RSI39.10
Earnings DateOct 28, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,481
Stock Exchange OTCMKTS
Ticker Symbol HYPMY
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.

Financial numbers in BRL Financial Statements

News

Brazil's Hypera announces new majority stakeholder group

Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.

3 months ago - Reuters

Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript

Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto...

7 months ago - Seeking Alpha

Hypera: Short-Term Pain For Long-Term Gain

Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caus...

11 months ago - Seeking Alpha

Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio

In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side Analys...

5 years ago - Seeking Alpha

A Brazilian-Focused Dividend Portfolio

Four out of thirty-seven Brazilian ADRs scored five out of five on the dividend binomial test and they have an equalweight average 2022 forward dividend yield of 7.6%.

5 years ago - Seeking Alpha